UNH · NYQ · Healthcare
UnitedHealth Group Incorporated
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 648.96
Market price
USD 376.90
Implied upside
+72.2%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 498.4bn | USD 555.0bn | USD 618.0bn | USD 688.1bn | USD 766.2bn | +11.4% |
| EBIT | USD 37.1bn | USD 41.3bn | USD 46.0bn | USD 51.2bn | USD 57.0bn | +11.4% |
| NOPAT | USD 29.3bn | USD 32.6bn | USD 36.3bn | USD 40.5bn | USD 45.1bn | +11.4% |
| Add depreciation & amortisation | USD 5.1bn | USD 5.7bn | USD 6.4bn | USD 7.1bn | USD 7.9bn | +11.4% |
| Less capital expenditure | USD -5.1bn | USD -5.7bn | USD -6.4bn | USD -7.1bn | USD -7.9bn | +11.4% |
| Less increase in working capital | USD 1.8bn | USD 2.0bn | USD 2.2bn | USD 2.4bn | USD 2.7bn | -11.4% |
| Free cashflow to firm | USD 31.1bn | USD 34.6bn | USD 38.5bn | USD 42.9bn | USD 47.8bn | +11.4% |
| Discount factor | 0.9615 | 0.8890 | 0.8220 | 0.7600 | 0.7026 | - |
| Present value | USD 29.9bn | USD 30.8bn | USD 31.7bn | USD 32.6bn | USD 33.6bn | +3.0% |
| Present Value Of The Forecast | USD 158.5bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.00% | US 10-year Treasury (^TNX) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 0.747 | Reported 0.622, pulled toward 1.0 (Blume) |
| Cost of equity | 9.11% | Risk-free + beta x equity risk premium |
| Cost of debt | 5.15% | Interest expense / average total debt |
| Market capitalisation | USD 338.3bn | 81.2% of capital |
| Total debt | USD 78.4bn | 18.8% of capital, book value as a proxy |
| Tax rate | 21.0% | Effective, capped at statutory |
| WACC | 8.16% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
75% of EV
- Forecast FCFF, final year
- USD 47.8bn
- Capex at depreciation, working capital in reinvestment
- USD 45.1bn
- Less reinvestment at g/ROIC (15.8% of NOPAT)
- USD -7.1bn
- Capitalised
- USD 37.9bn
- ROIC (reported)
- 15.8%
- Terminal value, undiscounted
- USD 687.4bn
- Terminal value, discounted
- USD 483.0bn
- Enterprise value
- USD 641.5bn
- Less net debt
- USD 50.3bn
- Equity value
- USD 591.2bn
Exit at 16.7x EBITDA
83% of EV
- Terminal value, undiscounted
- USD 1081.7bn
- Terminal value, discounted
- USD 760.1bn
- Enterprise value
- USD 918.5bn
- Less net debt
- USD 50.3bn
- Equity value
- USD 868.3bn
Spread between methods: 38%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 6.16% | 873.02 | 937.48 | 1019.24 | 1126.50 | 1273.66 |
| 7.16% | 711.50 | 749.07 | 794.46 | 850.49 | 921.53 |
| 8.16% | 598.44 | 621.74 | 648.96 | 681.25 | 720.23 |
| 9.16% | 514.85 | 529.89 | 547.02 | 566.76 | 589.81 |
| 10.16% | 450.54 | 460.48 | 471.59 | 484.11 | 498.35 |
Outlined: this model. Green text: above today's price of 376.90. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 11.4% | 0.1% | -11.2pp |
| EBIT margin | 7.4% | 4.5% | -2.9pp |
| Discount rate | 8.2% | 11.9% | +3.8pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.